Notable Upgrades: Apple (AAPL), Netflix (NFLX), Danaher (DHR), Amag Pharmaceuticals (AMAG), Gigamon (GIMO)

In a report issued to clients Monday, FBR Capital analysts said they believe Apple (AAPL)’s growth story around China is still underappreciated by the Street. The firm estimates that China will overtake the Americas as  Cupertino’s top geographic region by revenue in fiscal 2017. FBR has a 12-month base case estimate of $185/shr on the name.

Apple is currently printing a normal average trading volume with the issue trading 33.69 million shares, compared to the average volume of 48.73 million. The stock began trading this morning at $128.36 to currently trade 1.37% higher from the prior days close of $128.77. On an intraday basis it has gotten as low as $128.36 and as high as $130.72.

Apple Inc. shares are priced at 16.22x this year’s forecasted earnings, compared to the industry’s 25.53x earnings multiple. The company’s current year and next year EPS growth estimates stand at 39.40% and 7.20%, respectively. AAPL has a t-12 price-to-sales ratio of 3.50. EPS for the same period registers at $8.05.

Apple shares have advanced 2.49% in the last 4 weeks and 1.75% in the past three months. Over the past 5 trading sessions the stock has gained 0.90%.

The Cupertino California-based company, which is currently valued at $751.99 billion, has a median Wall Street price target of $150.00 with a high target of $195.00. Apple Inc. is up 55.77% year-over-year, compared with a 12.61% gain in the S&P 500.

Netflix, Inc. (NFLX) was reiterated a ‘Buy’ by Topeka Capital Markets analysts on Monday. The broker also raised its price target on the stock to $723 from $604.

Netflix Inc. shares are currently priced at 160.33x this year’s forecasted earnings, which makes them quite expensive compared to the industry’s 29.04x earnings multiple. Ticker has a forward P/E of 174.77 and t-12 price-to-sales ratio of 6.40. EPS for the same period is $3.84.

In the past 52 weeks, shares of Los Gatos, California-based video streaming firm have traded between a low of $315.54 and a high of $619.25 and are now at $615.19. Shares are up 78.17% year-over-year and 79.52% year-to-date.

Danaher Corp. (DHR) was reiterated as ‘Buy’ with a $108 from $100 price target on Monday by UBS.

On valuation measures, Danaher Corp. shares are currently priced at 24.19x this year’s forecasted earnings compared to the industry’s 18.15x earnings multiple. Ticker has a PEG and forward P/E ratio of 2.28 and 18.54, respectively. Price/Sales for the same period is $3.04 while EPS is $3.61. Currently there are 14 analysts that rate DHR a ‘Buy‘, 5 rate it a ‘Hold‘. No analyst rates it a ‘Sell‘. DHR has a median Wall Street price target of $100.00 with a high target of $114.00.

AMAG Pharmaceuticals, Inc. (AMAG) rating of ‘Outperform’ was reiterated today at Leerink Partners with a price target increase of $85 from $60 (versus a $61.97 previous close).

AMAG is up $3.72 at $65.69 on heavy volume. Midway through trading Monday, 1.10 million shares of AMAG Pharmaceuticals Inc. have exchanged hands as compared to its average daily volume of 727K shares. The stock ranged in a price between $62.44-$66.11 after having opened the day at $62.87 as compared to the previous trading day’s close of $61.97.

In the past 52 weeks, shares of Waltham, Massachusetts-based company have traded between a low of $17.26 and a high of $66.11. Shares are up about 46% since the beginning of the year.

Shares of Gigamon Inc. (GIMO) are up $1.74 to $32.23 in mid-day trading after Needham reiterated its ‘Buy’ rating and increased its 12-month base case estimate on the name by 4 points to $38 a share.

GIMO shares recently gained $1.76 to $32.25. In the past 52 weeks, shares of Santa Clara, California-based firm have traded between a low of $9.95 and a high of $32.28. Shares are up 73.53% year-over-year and 71.97% year-to-date.

Be the first to comment

Leave a Reply

Your email address will not be published.


*